GLPwatch
Glucagon-like peptide-1 receptors agonists (GLP1 RA).
J Pak Med Assoc · 2013
Last updated 2026-09-22Glucagon-like peptide-1 receptor agonists (GLP1 RAs) are a newer class of drugs used to treat type 2 diabetes. They work by improving blood sugar control through their mechanism of action, and this review compares them to other diabetes treatments like DPP-4 inhibitors while also discussing their clinical uses and future developments.
AI summary of the abstract below.
| Journal | J Pak Med Assoc, 2013 |
|---|---|
| Citations | 10 |
| Relative citation ratio | 0.37 |
| NIH percentile | 23 |
| Molecules | — |
Abstract
The glucagon-like peptide-1 receptors agonists (GLP1RA) are a relatively new class of drugs, used for management of type 2 diabetes. This review studies the characteristics of these drugs, focusing upon their mechanism of action, intra-class differences, and utility in clinical practice. It compares them with other incretin based therapies, the dipeptidyl peptidase-IV inhibitors, and predicts future developments in the use of these molecules, while highlighting the robust indications for the use of these drugs.
Verbatim abstract via PubMed 24392570 ↗